Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. (Nasdaq: TMST) is a clinical-stage biotechnology company focused on developing innovative cell therapy and small molecule product candidates to address high unmet medical needs in oncology and immunology. The company's website is www.tempesttherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tempest Therapeutics, Inc. does
In the company’s own words
Tempest Therapeutics, Inc. (Nasdaq: TMST) is a clinical-stage biotechnology company focused on developing innovative cell therapy and small molecule product candidates to address high unmet medical needs in oncology and immunology. The company's website is www.tempesttherapeutics.com.
In February 2026, Tempest expanded its pipeline through a strategic acquisition of dual-targeting chimeric antigen receptor T-cell (CAR-T) programs from Erigen LLC and Factor Bioscience Inc., significantly broadening its therapeutic portfolio. The company's lead cell therapy candidate, TPST-2003, is an autologous dual-targeting CAR-T therapy directed against CD19 and BCMA currently in clinical development for relapsed or refractory multiple myeloma. Clinical data as of January 2026 demonstrated a 100 percent complete response rate among evaluable patients in the REDEEM-1 Phase 1/2a trial, with a favorable safety profile including no Grade 3 or higher cytokine release syndrome.
Tempest's pipeline also includes TPST-2206, a dual-targeting CD70/CD70 CAR-T for solid tumors, alongside allogeneic programs TPST-3003 and TPST-3206, and an in vivo CAR-T program, TPST-4003, designed for immunology indications including lupus. These programs leverage a proprietary parallel dual-targeting CAR architecture intended to reduce tumor escape through antigen loss and improve targeting of heterogeneous tumor populations.
In small molecules, the company's lead candidate amezalpat (previously TPST-1120) is a selective peroxisome proliferator-activated receptor alpha antagonist that completed a Phase 1b/2 study in first-line hepatocellular carcinoma, demonstrating a six-month median overall survival improvement. The company received FDA Fast Track Designation and Orphan Drug Designation for amezalpat in 2025. TPST-1495, a dual EP2/EP4 prostaglandin receptor antagonist, is positioned to enter Phase 2 development in familial adenomatous polyposis with National Cancer Institute funding through the Cancer Prevention Clinical Trials Network.
Tempest operates as a smaller reporting company and employs a capital-efficient development strategy emphasizing partner-funded clinical trials and staged investment decisions based on clinical data generation. The company maintains exclusive worldwide rights to its small molecule programs outside certain territories and has established strategic partnerships with Novatim Immune Therapeutics and Factor Bioscience to advance its CAR-T portfolio.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- December
- CIK
- 1544227
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tempest Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tempest Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tempest Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tempest Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tempest Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”